Since proliferative vitreoretinopathy (PVR) is associated with an inflammatory reaction and interleukin-1 (IL-1) initiates a cascade of inflammatory mediators, we determined the intravitreal levels of IL-1 in experimental PVR. In the blood-trauma model of PVR in rabbits, we measured the intravitreal levels of IL-1Α and IL-1Β using a radioimmunoassay and performed immunohistochemical staining of cells from the vitreous. We found that on day 1 polymorphonuclear and from day 2 on mononuclear inflammatory cells predominated in the vitreous. IL-1Α-and IL-1Β-positive cells with a large cytoplasm were observed on days 4 and 8. However, the IL-1Α and IL-1Β concentrations in the vitreous did not exceed the radioimmunoassay sensitivity limit 8 h, 1, 2, 4 and 8 days after trauma, while in 2 control rabbits injected with additional endotoxins we found 5.6 and 8 ng/ml IL-1Β. We conclude that despite IL-1-positive cells, presumably macrophages, PVR is not associated with high levels of IL-1. No conclusions concerning the low levels of IL-1Α and IL-Β can be drawn due to the performance of the RIA.

Keywords:
Interleukin 1α, Interleukin 1β, Proliferative vitreoretinopathy, Rabbits
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.